Sei sulla pagina 1di 7

Partial Seizure - Pipeline Review, H2 2015 Is Released

Partial Seizure - Pipeline Review, H2 2015 Summary Global Markets Direct s, Partial Seizure - Pipeline
Review, H2 2015, provides an overview of the Partial Seizures therapeutic pipeline. This report provides
comprehensive information on the therapeutic development for Partial Seizure, complete with
comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news
and press releases. It also reviews key players involved in the therapeutic development for Partial
Seizure and special features on late-stage and discontinued projects. Global Markets Directs report
features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000
indications. The report is built using data and information sourced from Global Markets Directs
proprietary databases, Company/University websites, SEC filings, investor presentations and featured
press releases from company/university sites and industry-specific third party sources, put together by
Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation
following a stringent set of processes that ensures that all the profiles are updated with the latest set of
information. Additionally, processes including live news & deals tracking, browser based alert-box and
clinical trials registries tracking ensure that the most recent developments are captured on a real time
basis. The report enhances decision making capabilities and help to create effective counter strategies
to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to
produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed
or altered based on the availability and relevance of data for the indicated disease. Scope - The report
provides a snapshot of the global therapeutic landscape of Partial Seizure - The report reviews key
pipeline products under drug profile section which includes, product description, MoA and R&D brief,
licensing and collaboration details & other developmental activities - The report reviews key players
involved in the therapeutics development for Partial Seizure and enlists all their major and minor
projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the
Partial Seizure products under development by companies and universities/research institutes based on
information derived from company and industry-specific sources - Pipeline products coverage based on
various stages of development ranging from pre-registration till discovery and undisclosed stages - A
detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the
Partial Seizure pipeline on the basis of target, MoA, route of administration and molecule type - Latest
news and deals relating related to pipeline products Reasons to buy - Provides strategically significant
competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas
of leading companies - Identify and understand important and diverse types of therapeutics under
development for Partial Seizure - Plan mergers and acquisitions effectively by identifying key players of
the most promising pipeline - Devise corrective measures for pipeline projects by understanding Partial
Seizure pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and
expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove them from pipeline.

with
TOC
@
http://www.idatainsights.com/reports-landingpage.php?id=173386/mucopolysaccharidosis-iii-mps-iii-sanfilippo-syndrome-pipeline-review-h2-2015

Browse

To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173386/mucopolysaccharidosis-iii-mps-iii-sanfilippo-syndrome-pipeline-review-h2-2015


Table of Contents

Introduction 6
Global Markets Direct Report Coverage 6
Partial Seizure Overview 7
Therapeutics Development 8
Pipeline Products for Partial Seizure - Overview 8
Partial Seizure - Therapeutics under Development by Companies 9
Partial Seizure - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Partial Seizure - Products under Development by Companies 13
Partial Seizure - Companies Involved in Therapeutics Development 14
Advicenne Pharma 14
Catalyst Pharmaceutical Partners, Inc. 15
Eisai Co., Ltd. 16
Marinus Pharmaceuticals, Inc. 17
Novartis AG 18
SciFluor Life Sciences, LLC 19
SK Biopharmaceuticals Co., Ltd. 20
UCB S.A. 21
Partial Seizure - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
2

Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 30
brivaracetam - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
clobazam - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
CPP-115 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
everolimus - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ganaxolone - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
lacosamide - Drug Profile 43

Product Description 43
Mechanism of Action 43
R&D Progress 43
levetiracetam - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
MB-003 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
perampanel - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
selurampanel - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
SF-0034 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
YKP-3089 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
4

Partial Seizure - Recent Pipeline Updates 59


Partial Seizure - Dormant Projects 82
Partial Seizure - Discontinued Products 83
Partial Seizure - Product Development Milestones 84
Featured News & Press Releases 84
Nov 02, 2015: Eisai Presents Results From Phase III Trial of Antiepileptic Drug Perampanel as Adjunctive
Therapy for Refractory Partial-Onset Seizures Conducted in Asia Including Japan 84
Apr 20, 2015: Important UCB presents data on VIMPAT at the 2015 American Academy of Neurology
Meeting 85
Jan 05, 2015: Phase III Trial of Antiepileptic Drug Perampanel As Adjunctive Therapy In Patients With
Refractory Partial-Onset Seizures Conducted In Asia Including Japan And China Meets Primary Endpoint
87
Dec 08, 2014: UCB announces first presentation of primary data from latest Phase 3 study evaluating
brivaracetam as adjunctive treatment of partial-onset seizures in epilepsy 87
Apr 25, 2014: Eisai Presents Research on FYCOMPA (perampanel) CIII at The American Academy of
Neurology's 66th Annual Meeting 89
Feb 10, 2014: Fycompa to be Resubmitted Early to German Federal Joint Committee for Additional
Benefit Assessment 89
Jan 06, 2014: Eisai Announces Launch of Antiepileptic Drug Fycompa in U.S. 90
Jan 02, 2014: Eisai Announces U.S. Availability of FYCOMPA CIII an Adjunctive Treatment for PartialOnset Seizures in Patients with Epilepsy Age 12 and Older 91
Nov 20, 2013: New data from UCB's epilepsy portfolio to be highlighted at the 67th Annual Meeting of
the American Epilepsy Society 92
Appendix 94
Methodology 94
Coverage 94
Secondary Research 94
Primary Research 94
Expert Panel Validation 94
Contact Us 94
Disclaimer 95
5

Read
More
http://www.idatainsights.com/reports-landingpage.php?id=173386/mucopolysaccharidosis-iii-mps-iii-sanfilippo-syndrome-pipeline-review-h2-2015
About Us:
iData Insights which operates under Precision Research and Consulting Private Limited is a leading
market research information aggregator and marketing research consulting firm. We conduct both
primary and secondary research. Our work does not end with research it is also involved in distributing
reports for different companies . We provide actionable recommendations and provide our expertise for
business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and
discovery, and then be their guide in the implementation of changes that will make a difference to their
bottom line.
ContactUs:
iData Insights
Tel: 1-866-237-2965
Web: http://www.idatainsights.com
Email: info@idatainsights.com
About iData Insights
We work around the clock until our clients are completely satisfied with their promised results. It is our
mission to provide timely services coupled with acute client care to create a long-lasting relationship
with you. We deliver on our promise to provide results that are essential to the success of your
company. We believe that by doing so, we will earn the trust of our clients for future projects